About vorasidenib
Isocitrate dehydrogenase inhibitor
Used for
- Treats certain IDH-mutant grade 2 astrocytomas or oligodendrogliomas after surgery.
Usual adult dose
40 mg by mouth once daily, until disease progression or unacceptable toxicity.
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Liver enzyme increases
Important warnings
- Can cause serious liver injury; liver tests are needed before and during treatment.
- Avoid strong or moderate CYP1A2 inhibitors and smoking, which can alter drug levels.
- May cause fetal harm; effective contraception is recommended during treatment and afterward.
- Avoid breastfeeding during treatment and for two months after the last dose.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for three months afterward.
Breastfeeding
Do not breastfeed during treatment or for two months after the last dose.
Interactions
- CYP1A2 inhibitors, including fluvoxamine, can increase vorasidenib levels.
- Smoking can reduce vorasidenib levels and effectiveness.
- Vorasidenib can reduce effectiveness of hormonal contraceptives.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.